BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 196.8 USD | -0.70% |
|
-3.98% | -23.95% |
| Apr. 15 | Argus Adjusts Biogen's Price Target to $240 From $315 | MT |
| Apr. 15 | Goldman Sachs Cuts Biogen's Price Target to $393 From $400 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
196.8
USD
Average target price
294.9
USD
Spread / Average Target
+49.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.95% | 28.61B | |
| -4.17% | 86.99B | |
| +4.34% | 40.68B | |
| +50.32% | 24.1B | |
| -5.09% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -14.91% | 12B | |
| -4.57% | 7.94B | |
| -18.83% | 7.43B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Sector Update: Health Care Stocks Drifting Lower Monday Afternoon
